Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 418 | 102 | 357 | 869 | 2,099 |
| Other current assets | 7 | 7 | 29 | 29 | 29 |
| TOTAL | $576 | $280 | $635 | $1,020 | $2,285 |
| Non-Current Assets | |||||
| PPE Net | 7 | 10 | 13 | 17 | 21 |
| Other Non-Current Assets | 34 | 34 | 44 | 44 | 44 |
| TOTAL | $41 | $44 | $57 | $61 | $65 |
| Total Assets | $617 | $323 | $692 | $1,081 | $2,350 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 227 | 275 | 387 | 183 | 137 |
| Accrued Expenses | 488 | 266 | 287 | 201 | 215 |
| Other current liabilities | 32 | 121 | 167 | 106 | 137 |
| TOTAL | $747 | $662 | $841 | $491 | $490 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,100 | 1,112 | 2,230 | 2,202 | 4,226 |
| TOTAL | $1,100 | $1,112 | $2,230 | $2,206 | $4,230 |
| Total Liabilities | $1,847 | $1,774 | $3,071 | $2,697 | $4,720 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 121 | 103 | 83 | 80 | 80 |
| Common Shares | 27 | 22 | 20 | 20 | 20 |
| Retained earnings | -12,220 | -10,937 | -9,816 | -8,871 | -9,444 |
| Other shareholders' equity | 2,633 | 2,301 | 782 | 782 | 782 |
| TOTAL | $-1,229 | $-1,451 | $-2,379 | $-1,615 | $-2,370 |
| Total Liabilities And Equity | $617 | $323 | $692 | $1,081 | $2,350 |